ArticleLeukemia2023

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.

Michael J Mauro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.